Core Scientific, Inc. — Form 8-K Summary
Report date: September 7, 2023 (filed September 8, 2023). The filing was furnished under Item 7.01, Regulation FD Disclosure. Core Scientific and certain affiliates remained debtors-in-possession in Chapter 11 proceedings initiated on December 21, 2022.
Business Context and Reporting Period
The filing reports developments in the Company’s Chapter 11 restructuring and references production and operations updates for August 2023. The August operating update was provided in an attached press release, but the press release’s detailed contents are not included in the filing text provided.
Financial and Operating Metrics
- The filing does not provide clear figures for revenue, profit, cash flow, margins, debt balances, liquidity, bitcoin production, hashrate, or other operating metrics.
- The Company’s common stock and warrants traded exclusively on the OTC Pink Marketplace beginning January 3, 2023 under CORZQ and CRZWQ, respectively.
- The filing references debtor-in-possession financing and a potential replacement facility but does not state facility amounts, available liquidity, or financing terms.
Material Developments
- On September 7, 2023, the Debtors filed a Second Amended Joint Chapter 11 Plan of Reorganization and related Second Amended Disclosure Statement with the U.S. Bankruptcy Court for the Southern District of Texas.
- The plan describes the proposed restructuring, events leading to the Chapter 11 cases, anticipated creditor solicitation, and other restructuring matters.
- As of the filing date, the Company had agreements in principle regarding material restructuring terms and plan support with certain, but not all, key stakeholders. Discussions with remaining stakeholders were continuing.
- The Second Amended Disclosure Statement had been submitted for Bankruptcy Court approval but had not been approved as of the filing date.
- The filing and related plan documents were not a solicitation of votes. Any solicitation would occur only after required Bankruptcy Court approval and in accordance with applicable law.
Guidance, Outlook, Risks, and Unusual Items
- The Company intended to pursue the restructuring under the Second Amended Plan, but stated that approval, successful consummation, emergence from Chapter 11, and completion on the proposed terms were not assured.
- Key risks include Bankruptcy Court rulings, creditor and third-party actions, the duration and effects of the Chapter 11 cases, adverse effects on liquidity and operations, increased professional costs, and the Company’s ability to achieve significant operating cash flows.
- Additional risks include finalization and receipt of replacement debtor-in-possession financing, satisfaction of financing conditions, acceleration of debt obligations, and volatility and limited liquidity associated with OTC Pink trading.
- The Second Amended Plan and Disclosure Statement were subject to further amendment or supplementation and should not be relied upon as final.
Investor Verification Checklist
- Verify the full terms, creditor recoveries, capitalization treatment, and conditions of the Second Amended Plan and Disclosure Statement in Exhibits 99.1 and 99.2.
- Confirm whether the Bankruptcy Court approved the Disclosure Statement and subsequently confirmed the plan.
- Review the August 2023 production and operations press release in Exhibit 99.3 for operating metrics not reproduced in this filing text.
- Verify the status, amount, availability, and conditions of debtor-in-possession or replacement financing.
- Assess the impact of Chapter 11 on debt obligations, liquidity, operating continuity, and the value and trading conditions of CORZQ and CRZWQ.